Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
about
Adjuvant radiotherapy following radical prostatectomy for prostate cancerPractices and impact of primary outcome adjustment in randomized controlled trials: meta-epidemiologic studyRadiation Therapy after Radical Prostatectomy: Implications for CliniciansGaps between Evidence and Practice in Postoperative Radiotherapy for Prostate Cancer: Focus on Toxicities and the Effects on Health-Related Quality of LifeRationale and development of image-guided intensity-modulated radiotherapy post-prostatectomy: the present standard of care?Integrating Geriatric Assessment into Decision-Making after Prostatectomy: Adjuvant Radiotherapy, Salvage Radiotherapy, or None?Robotic-Assisted Laparoscopic Radical ProstatectomyOptimal management of prostate cancer with lethal biology--state-of-the-art local therapyFROGG high-risk prostate cancer workshop: patterns of practice and literature review. Part II post-radical prostatectomyManagement of patients with biochemical recurrence after local therapy for prostate cancerExternal beam radiotherapy for localized prostate cancerProstate cancer: ESMO Consensus Conference Guidelines 2012A Urologist's Personal View of Prostate CancerHow Precisely Can Prostate Cancer Be Managed?Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomyAdjuvant and salvage radiotherapy after prostatectomy: a systematic review and meta-analysis.Effect of Preoperative Risk Group Stratification on Oncologic Outcomes of Patients with Adverse Pathologic Findings at Radical ProstatectomyPrognostic outlier genes for enhanced prostate cancer treatment.Reconsidering adjuvant versus salvage radiation therapy for prostate cancer in the genomics era.Adjuvant and salvage radiation therapy after prostatectomy: investigating beliefs and practices of radiation oncologists.Radiation therapy after radical prostatectomy for prostate cancer: evaluation of complications and influence of radiation timing on outcomes in a large, population-based cohort.Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapyVariation in the use of postoperative radiotherapy among high-risk patients following radical prostatectomy.Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis.Treatment-related complications of radiation therapy after radical prostatectomy: comparative effectiveness of intensity-modulated versus conformal radiation therapy.Implementation of an image guided intensity-modulated protocol for post-prostatectomy radiotherapy: planning data and acute toxicity outcomes.No increase in toxicity of pelvic irradiation when intensity modulation is employed: clinical and dosimetric data of 208 patients treated with post-prostatectomy radiotherapyTesting the Assessment of New Radiation Oncology Technology and Treatments framework using the evaluation of post-prostatectomy radiotherapy techniques.Adjuvant radiotherapy after prostatectomy for prostate cancer in Japan: a multi-institutional survey study of the JROSG.Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases.Counseling patients about sexual health when considering post-prostatectomy radiation treatment.Clinician-led improvement in cancer care (CLICC)--testing a multifaceted implementation strategy to increase evidence-based prostate cancer care: phased randomised controlled trial--study protocolTreatment-related toxicity and symptom-related bother following postoperative radiotherapy for prostate cancer.Shared responsibility for treatment-related morbidity for prostate cancerAdjuvant medical therapy for prostate cancer.Salvage radiotherapy for patients with PSA relapse following radical prostatectomy: issues and challenges.Identification of men with the highest risk of early disease recurrence after radical prostatectomyProstate cancer radiotherapy in Austria: overview on number of patients, intention to treat, and treatment techniques based on data from 2007.Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.What are the outcomes of radical prostatectomy for high-risk prostate cancer?
P2860
Q24234347-02B44A11-C462-4B55-A117-163C462CBE26Q24289045-1CC0EEDB-5763-4D5A-A920-1F7FB29097E4Q26744531-F4D6D4B0-B337-4DCC-817A-6A6547A05D5DQ26751574-F93E38AF-E548-4636-B008-6ACBEBBD12F4Q26774847-07C2D056-8B1B-496D-8F90-7730ED029A76Q26777128-D0B6594B-D87B-497B-8675-7485B68E3D9EQ26782257-262A3489-56C4-4A83-BFFE-8F888BCD6290Q26801188-BDC0F395-4366-4DEB-9BBC-9830ED6ED544Q26827690-84008BD8-4F11-4169-B5BF-58439165F8CEQ26849220-8FB83FBA-8C67-4009-AC59-2DAC3DDA93E0Q26853068-A094134C-16C7-4AA7-B582-22571A7E583AQ27022847-27F720C4-AF5B-4C40-BFEA-187FA629DDA9Q28072919-3597EF54-9BD7-4CD6-8EAD-E8CE09F8362BQ28078942-4CAB36FF-AB04-46B8-A8F8-3BC8F5A065D8Q28534277-5A776687-6A29-4B5C-BE56-77403010FC27Q28541950-9BD88353-3960-4FF9-A88B-F4CC5C882BB9Q28554583-B562AC85-FB59-45D6-AC26-BB3C8032B51AQ30244674-F3CE21DE-E38D-47EC-A791-DC7232E6AEC0Q30276626-6CD2986C-CE3B-4137-BF29-D89085C12136Q30278648-68EBE4DE-14CB-4042-B0F9-8893C29A00C6Q30300626-EBE41DA7-AD21-41B6-BE11-EC2A263DD86FQ30371634-A7B1CFCF-E3A0-454D-894A-15BFBEF6EAA7Q30385364-19F59759-9F03-4585-839F-EB06AAE2B2BBQ30405851-D2E95054-601A-4862-8FAF-E10B40FB7DD4Q30413727-77571918-AFF1-46B1-9998-1956E105CCF3Q30656223-A03A63F6-1B43-4EF9-BD46-E1C703E3657DQ31083823-965D7D64-04E0-4A16-AB32-5ECA573E3D93Q33390727-3F772C7C-2C26-4FBE-927C-4F215121D9CAQ33582634-76236C5A-9B8C-4349-B307-67D54EF7A58CQ33705993-0AE6F123-423B-4CB7-9839-FCC5E0265E0AQ33710312-31031674-EF61-49DA-9DB5-FC15FAE74319Q33722746-CB2403D7-D6DF-45DE-A644-1D34DE823113Q33754012-C7A9362E-4E80-46EB-9D8D-6134A8413D0FQ33754017-05EF405F-C992-427C-A467-4F03289429BFQ33758771-BD82CCB2-EABC-49AD-9F24-25EC70FC1CBEQ33766462-8B095293-ACBC-46F9-905A-F45BD459A648Q33825388-232D1314-AC81-482B-A113-710C53B7B49AQ33887010-F8281E0E-C167-41E6-A277-AF5BF4523DDBQ33898869-A03DFFD2-2DAE-45BD-89B6-F9A5DE2D6442Q33927594-F8CCF2A7-71CF-4760-93EB-F57A1F7C2CF2
P2860
Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Phase III postoperative adjuva ...... tigen: ARO 96-02/AUO AP 09/95.
@en
Phase III postoperative adjuva ...... tigen: ARO 96-02/AUO AP 09/95.
@nl
type
label
Phase III postoperative adjuva ...... tigen: ARO 96-02/AUO AP 09/95.
@en
Phase III postoperative adjuva ...... tigen: ARO 96-02/AUO AP 09/95.
@nl
prefLabel
Phase III postoperative adjuva ...... tigen: ARO 96-02/AUO AP 09/95.
@en
Phase III postoperative adjuva ...... tigen: ARO 96-02/AUO AP 09/95.
@nl
P2093
P356
P1476
Phase III postoperative adjuva ...... tigen: ARO 96-02/AUO AP 09/95.
@en
P2093
Alessandra Siegmann
Axel Hinke
Axel Semjonow
Christian Rübe
Dirk Bottke
Horst Jürgen Feldmann
Kurt Miller
Lothar Weissbach
Manfred Wirth
Michael Stöckle
P304
P356
10.1200/JCO.2008.18.9563
P407
P577
2009-05-11T00:00:00Z